For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

What are the effects (benefits and harms) of palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children? Background RSV is the main cause of acute respiratory infections ...

Flu, COVID-19, and Respiratory Syncytial Virus (RSV): If you are ill with a respiratory virus, PLEASE STAY HOME and away from others. This will help everyone. If you are in the clinical portion of ...

Fiona Havers, a physician considered a senior subject-matter expert on respiratory diseases and vaccines, led the CDC’s surveillance of hospitalizations for coronavirus and respiratory syncytial ...

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infections for which effective treatment options remain limited. Herein, we employed a computational structure-based ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...